Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate  by Aime, S. et al.
and will be included on the KDIGO website when
published.
1. Singh. Hemoglobin level in dialysis patients: Revisiting the normal
hematocrit study. Kidney Int 2007 (in press).
2. Vanbelleghem H, Vanholder R, Levin NW et al. The kidney disease:
improving global outcomes website: comparison of guidelines as a tool
for harmonization. Kidney Int 2007; 71: 1054–1061.
3. Besarab A, Bolton WK, Browne JK et al. The effects of normal as
compared with low hematocrit values in patients with cardiac disease
who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:
584–590.
4. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level
in patients with chronic kidney disease and anemia. N Eng J Med 2006;
355: 2071–2084.
5. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin
alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085–2098.
R Vanholder1, H Vanbelleghem1, N Lameire1 and G Eknoyan1
1Department of Nephrology, University of Ghent, Waregem, Belgium
Correspondence: H Vanbelleghem, Department of Nephrology, University of
Ghent, Walstraat 178, 9870 Zulte, Belgium.
E-mail: hilde.vanbelleghem@telenet.be
Advisory about gadolinium calls
for caution in the treatment of
uremic patients with lanthanum
carbonate
Kidney International (2007) 72, 1162–1163; doi:10.1038/sj.ki.5002503
To the Editor: The FDA issued advisories concerning the risk
for patients with renal failure who receive gadolinium-chelates
for developing a sometimes fatal disorder called Nephrogenic-
Fibrosis-Dermopathy (NFD)/Nephrogenic-Systemic-Fibrosis
(NSF).1 Although the disease mechanism has yet to be
elucidated, there is consensus that NFD/NFS could be associated
to the release of free gadolinium in the tissues. The cells may act
as sponges for the free-gadolinium ions by exploiting (and thus
interfering) the calcium regulatory machinery.2
Gadolinium is the 64th element of the periodic table at the
center of the lanthanide series (14 elements) (Figure 1). It is
known that all the members of the series display very close
physical-chemical characteristics yielding trivalent ions
whose (very small) differences in their chemical behavior
are essentially determined by the changes in the mass to
charge ratio.3
The use of lanthanum-carbonate salts as chelating agents
might have some analogies with what we are learning from
the gadodiamide story. Lanthanum-carbonate has been
selected for its insolubility. However, it has been reported
that lanthanum concentration is increased 10-fold in blood
and fivefold in bone after short-term supplementation.4,5
What’s about long-term treatments? Equilibrium shifts and
transmetallation reactions may lead to unexpected interfer-
ences with basic physiological processes and the upsurge of
diseased states as shown with gadodiamide. Clearly, more
work appears necessary to assess potential toxic effects
associated to the use of lanthanide-based drugs.
By now, as many uremic patients are taking lanthanum-
carbonate as phosphate-binder, nephrologists are strongly
recommended to look at any symptoms evoking NSF/NSD in
post-marketing drug-safety surveillance system.
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Figure 1 | Periodic table of the elements: gadolinium (Gd) belongs to the lanthanide series.
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Replacing the short ammonium
chloride test
Kidney International (2007) 72, 1163; doi:10.1038/sj.ki.5002506
To the Editor: We applaud Walsh and colleagues’ interest in
replacing the unpalatable ammonium chloride (NH4Cl) test
of urine acidification capacity for the diagnosis of distal renal
tubular acidosis (dRTA).1 We note that their study showed
perfect concordance with the more modern fludrocortisone/
furosemide test in a group of patients previously known to
have dRTA, and in healthy volunteers.
Recurrent renal stone formers have a relatively high
incidence of an impaired capacity to acidify their urine with
reported prevalences ranging from 6 to 20%, depending on
the selection criteria employed.2 Hence, further investigation
in this group is often warranted. However, in clinical practice,
any new test must have sufficient positive and negative
predictive value if it is to be useful as a diagnostic rather than
confirmatory tool. To address this, we have performed a
similar study in 10 adult patients presenting with clinical
suspicion of dRTA and 10 healthy volunteers. All 10 patients
had recurrent nephrolithiasis and/or nephrocalcinosis; three
had a family history of nephrolithiasis. All subjects had
random urine pH45.5. All subjects underwent both
fludrocortisone/furosemide testing (1 mg 10 h pretest/40 mg
day of test) and NH4Cl testing on separate occasions at the
same time of day. All potentially confounding drugs were
stopped the week before testing.
All 10 healthy volunteers were able to acidify their urine to
pHo5.3 with both tests (Figure 1). However, while all 10
patients acidified normally with NH4Cl, with fludrocorti-
sone/furosemide only 3 of 10 reduced their urine pH too5.3
(or indeed o5.5, the pH used in the original NH4Cl report;3
Figure 1). Thus, the negative predictive value of the newer
test for disease was 100% but the positive predictive value
was very much less.
These data suggest that the fludrocortisone/furosemide
test is a useful screening tool to rule out dRTA, but failing
this test does not necessarily imply that dRTA is present. The
only difference in our protocol was the prior administration
of fludrocortisone, as in Walter et al.’s earlier report of this
test in healthy individuals, where all passed.4 With a half-life
of 18–36 h, this difference is unlikely to account for the
disparate results.
We therefore counsel caution in extrapolating Walsh’s
conclusions to the at-risk clinical population. We recom-
mend instead that in adults at least, the fludrocortisone/
furosemide test be used first, with a follow-up NH4Cl test if
acidification is not achieved.
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Figure 1 | Paired pretest and nadir urine pH values for normal controls (closed symbols) and patients with nephrolithiasis and/or
nephrocalcinosis (open symbols) subjected to NH4Cl (diamonds) and fludrocortisone/furosemide (squares) tests.
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